BioWorld Asia

March 3, 2004

Oncology-Focused Igeneon Raises EUR26.7M, Ponders IPO

Igeneon AG raised €26.7 million in a third-round venture financing and landed Burrill & Co., of San Francisco, as a co-lead investor. (BioWorld International) Read More

Active Biotech Cuts Work Force; Focus Now On Current Portfolio

How Salmonella Coaxes Gut Cell To Give Warm Embrace

Monsanto GM Rapeseed Product Receives EU Scientific Clearance

Phytopharm Raises £6.5M, Plans Partnering Of Obesity Drug P57

NCI Begins Exploratory Cancer Trials With Xenova's Tariquidar

Start-Up Vaxon Seeking EUR7M For Novel Cancer Vaccines

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...